The study compared treatment with dual HER2 inhibitors to a standard EGFR inhibitor-based treatment in patients with previously treated, HER2-positive disease. It found that the HER2 inhibitor treatment can provide similar benefit with less toxicity.
Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.
The Howard Hughes Medical Institute has named Fred Hutch Cancer Center postdoctoral researcher Grant King, PhD, a Hanna H. Gray Fellow — investing up to…
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a…
AACR grants fund cancers researchers worldwide at every career stage, representing a commitment to the understanding of cancer biology, prevention, early detection, interception, and cure.
Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.
The functioning of US government is facing a systemic crisis
Comparing the UK & US Approaches to First-Line Treatment in Hodgkin Lymphoma
Being well-informed about clinical trials was associated with a greater willingness to participate.
